Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 January 2020Website:
http://www.i-mabbiopharma.comNext earnings report:
16 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:57:41 GMTDividend
Analysts recommendations
Institutional Ownership
IMAB Latest News
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that Gerald Falchook, MD, and the team at I-Mab's partner for ragistomig (or “ABL503”), ABL Bio (KOSDAQ: 298380), will present a poster related to Phase 1 data for ragistomig at the 2024 American Society for Clinical Oncology Annual Meeting (“ASCO 2024”), taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL.
I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive up to $80 million in cash consideration from its divested China operation. I-Mab's core assets will consist of three global Immuno-Oncology programs, including uliledlimab, which has shown promising Phase 2 NSCLC clinical trial data.
I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarket trading.
Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has a late-stage pipeline with 20 assets and over $400 million in cash, but its market cap is only around $126 million. The company's advanced products, such as Felzartamab and Eftansomatropin Alfa, have limited trial data available, making it difficult for American investors to assess the company properly.
A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arbitration hearing as a way of surreptitiously getting a look at its proprietary research.
I-Mab (NASDAQ:IMAB ) Q4 2022 Earnings Conference Call March 31, 2023 8:15 AM ET Company Participants Tyler Ehler - Senior Director of Investor Relations Andrew Zhu - Acting Chief Executive Officer Richard Yeh - Interim Chief Financial Officer and Chief Operating Officer Jingwu Zang - Founder and Chairman Conference Call Participants Kelly Shi - Jefferies Joseph Catanzaro - Piper Sandler Louise Chen - Cantor Fitzgerald Andres Maldonado - H.C. Wainwright Tyler Ehler Good morning to everyone and thank you for joining us this morning.
What type of business is I-Mab?
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
What sector is I-Mab in?
I-Mab is in the Healthcare sector
What industry is I-Mab in?
I-Mab is in the Biotechnology industry
What country is I-Mab from?
I-Mab is headquartered in United States
When did I-Mab go public?
I-Mab initial public offering (IPO) was on 17 January 2020
What is I-Mab website?
https://www.i-mabbiopharma.com
Is I-Mab in the S&P 500?
No, I-Mab is not included in the S&P 500 index
Is I-Mab in the NASDAQ 100?
No, I-Mab is not included in the NASDAQ 100 index
Is I-Mab in the Dow Jones?
No, I-Mab is not included in the Dow Jones index
When does I-Mab report earnings?
The next expected earnings date for I-Mab is 16 August 2024